Oxurion NV announced that it has enrolled more than two-thirds of the planned total enrollment in its KALAHARI Phase 2, Part B clinical trial (KALAHARI trial). The KALAHARI trial is evaluating Oxurions novel plasma kallikrein (PKal) inhibitor THR-149 as a potential treatment for patients with diabetic macular edema (DME) who respond suboptimally to anti-VEGF therapy, the current standard of care. Oxurions investigators have successfully recruited 80 of the 108 (74%) patients planned for this trial, for which Oxurion anticipates reporting top-line data in the fourth quarter of 2023.

This milestone builds on the recommendation from an Independent Data Monitoring Committee (IDMC) in December 2022 that the KALAHARI trial should continue based upon the outcome of a pre-specified futility analysis that included an evaluation of interim efficacy and safety data from 31 patients at the three-month time point.